310 likes | 340 Views
This presentation outlines the strategies and goals to end the AIDS epidemic in Zimbabwe by achieving the 90.90.90 targets. It discusses testing yield, treatment advancements and challenges, sustaining viral suppression, financing the response, and concludes with a roadmap for success. The goal is to significantly reduce new HIV infections and AIDS-related deaths in the country, ensuring a healthier future for all citizens. By focusing on community delivery, patient-driven diagnostics, and targeted testing strategies, Zimbabwe aims to reach ambitious but achievable treatment targets by 2030.
E N D
Fast-track to ending AIDS in Zimbabwe: 90.90.90 opportunities Michael Bartos (bartosm@unaids.org) UZ-UCSF Annual Research Day 17 April 2015
Outline 1. Why the 90.90.90 TARGETS?2. TESTING – SHIFTING TO YIELDS3. TREATMENT ACHEIVEMENTS AND CHALLENGES4. SUSTAINING VIRAL SUPPRESSION5. FINANCING THE RESPONSE6. CONCLUSION
New HIV infections in low- and middle-income countries, 2010–2030, with achievement of ambitious Fast-Track Targets, compared to maintaining 2013 coverage
AIDS-related deaths in low- and middle-income countries, 2010–2030, with achievement of ambitious Fast-Track Targets, compared to maintaining 2013 coverage
Ending the AIDS epidemic: A working definition ‘Ending the AIDS epidemic as a public health threat by 2030’ is provisionally defined as ‘reducing new HIV infections, stigma and discrimination experienced by people living with HIV and key populations, and AIDS-related deaths by 90% from 2010 levels, such that AIDS no longer represents a major threat to any population or country’
By 2020… 90% of all people living with HIV will know their HIV status 90% of all people diagnosed with HIV will receive sustained antiretroviral therapy. 90% of all people receiving antiretroviral therapy will have durable suppression.
What would ending AIDS targets look like for Zimbabwe – 2030 results ? New infectionsdown 13% year on year 100,000 in 2010 currently (2013) 69,000 to 63,000 in 2015 (current projection) to 25,000 in 2020 and 10,000 in 2030 AIDS deaths down from 90,000 in 2010 currently (2013) 64,000 to 27,000 in 2015 (current projection) to 9,000 in 2030
Outline 1. Why the 90.90.90 TARGETS?2. TESTING – SHIFTING TO YIELDS3. TREATMENT ACHEIVEMENTS AND CHALLENGES4. SUSTAINING VIRAL SUPPRESSION5. FINANCING THE RESPONSE6. CONCLUSION
Testing: volume or yield? Current test volume 2.5m, 2018 target 3m annually
Testing – results from the 2013 MICS % of sexually active young people tested in past 12 months All – ever tested Tested past 12 mths
Korenromp and Stover, Democratizing Testing, UNAIDS April 2015
Outline 1. Why the 90.90.90 TARGETS?2. TESTING – SHIFTING TO YIELDS3. TREATMENT ACHEIVEMENTS AND CHALLENGES4. SUSTAINING VIRAL SUPPRESSION5. FINANCING THE RESPONSE6. CONCLUSION
Zimbabwe ART coverage targets 2014-2016 Ending AIDS 81% coverage target
Outline 1. Why the 90.90.90 TARGETS?2. TESTING – SHIFTING TO YIELDS3. TREATMENT ACHEIVEMENTS AND CHALLENGES4. SUSTAINING VIRAL SUPPRESSION5. FINANCING THE RESPONSE6. CONCLUSION
Retention of Patients Initiating ART During 2007-2009, Zimbabwe • Good retention in care observed in a retrospective cohort study in a nationally representative sample of patients initiating ART between 2007 and 2009 • 69% of patients were continuing ART treatment at 24 months, whereas 7% had died and 24% were lost to follow-up (MOHCW, 2012)
90% of those on ART virally suppressed: trade offs? • Initiation vs. retention • Routine viral load vs. ‘on demand’ • Maximally effective regimen vs. maximally forgiving regimen
Community ART refill groups Model • self-selecting patient groups (7-14) • one representative picks up ARVs for the group on quarterly basis • group contribute money for transport/ lunch/in kind support (eg work their fields) Results: 9 months pilot evaluation (n=207) • 100% retention, 99% virally suppressed • Time saving: normally 45mins waiting, 50 mins with staff (nurse, counsellor, pharmacist); ART refill groups: 30 mins to serve 8 patients – saving >10 person/hours per day in a busy 3 person clinic • Cost savings to patients from $14 per month to $48 (more remote areas) • Secondary benefits in increased resilience, reduced stigma, more participation in health governance.
Outline 1. Why the 90.90.90 TARGETS?2. TESTING – SHIFTING TO YIELDS3. TREATMENT ACHEIVEMENTS AND CHALLENGES4. SUSTAINING VIRAL SUPPRESSION5. FINANCING THE RESPONSE6. CONCLUSION
Building on past achievements: funds invested in AIDS programmes in low- and middle-income countries, 1986–2013 PEPFAR: The United States President’s Emergency Plan for AIDS Relief Sources: UNAIDS estimates, UNAIDS–Kaiser Family Foundation reports on financing the response to HIV in low- and middle-income countries, GARPR 2014, philanthropic resource tracking reports from Funders Concerned About AIDS, reports from the Global Fund and UNITAID.
Potential room for expansion: per capita health assistance, selected countries Zimbabwe
Public resource Availability for AIDS in Zimbabwe, 2009-2016, US $ million
Resource needs for AIDS 2015-2025 in two different scenarios: current coverage and enhanced, more efficient coverage
Sustainability will require much more community delivery Patient-driven diagnostics and regimen switching Testing – shift from undifferentiated to targeted yield No one turned away More money will be needed (also to turn off the tap) conclusion